Sunday, May 6, 2012

Popular Diabetes Treatments Could Trigger Pancreatitis and Pancreatic Cancer

Popular Diabetes Drugs and Treatments May Trigger Pancreatitis and Pancreatic Cancer: Januvia Users, Janumet Users, Victoza Users, and Byetta Users Should Be Aware of Potential Risks and Consult With Their Doctors Regarding Early Detection of Pancreas Problems and Pancreatic Cancer by Texas Diabetes Drug Cancer Lawyer Jason S. Coomer

Recent studies have indicated that a growing number of popular diabetes drugs including Januvia, Janumet, Victoza, and Byetta may cause pancreas problems including Pancreatitis and Pancreatic Cancer.  Diabetics that are taking Januvia, Janumet, Victoza, or Byetta should be aware of this potential health risk and be aware of symptoms that may suggest pancreas problems.  The warning signs of pancreatitis can include: 1) Upper abdominal pain that radiates into the back. Patients may describe this as a "boring sensation" that may be aggravated by eating, especially foods high in fat. 2) Swollen and tender abdomen 3) Nausea and vomiting 4) Fever  and 5) Increased heart rate.

Januvia Users, Janumet Users, Victoza Users, and Byetta users should be aware of these symptoms as well as any symptoms of pancreatic cancer including weight loss, dark urine and clay-colored stools, back pain, and jaundice.  Unfortunately, pancreatic cancer is difficult to diagnose, and the diagnosis is often made late in the course of the disease.  Early detection of pancreatic cancer is essential and will greatly improve a person's chances of surviving the disease.  Frequent and good communication with your doctor and awareness of you body are essential.  Additionally, make sure that all health care providers are aware that you are taking or have taken Januvia, Janument, Victoza, or Byetta.



Pancreatic cancer is the fourth leading cause of cancer death for both men and women and is one of the most deadly of all types of cancer. The diabetes drugs, Januvia and Janumet, may cause an increased risk of pancreatic cancer in patients using Januvia.

Popular Diabetes Treatment Could Trigger Pancreatitis, Pancreatic Cancer, Study Suggests

"ScienceDaily (Apr. 30, 2009) — A drug widely used to treat Type 2 diabetes may have unintended effects on the pancreas that could lead to a form of low-grade pancreatitis in some patients and a greater risk of pancreatic cancer in long-term users, UCLA researchers have found."


The consumer group, Public Citizen, has filed a petition with the Food and Drug Administration (FDA) requesting that the agency immediately remove the diabetes drug, Vicoza, from the market the increasingly prescribed diabetes drug Victoza (liraglutide [rDNA origin] injection) because it puts patients at higher risk of thyroid cancer, pancreatitis, serious allergic reactions and kidney failure that outweigh any documented clinical benefits.

Consumer Group to FDA: Take Victoza off the Market

"April 20, 2012 -- Public Citizen, the Washington, D.C.-based consumer advocacy group, is petitioning the FDA to immediately remove the type 2 diabetes drug Victoza (liraglutide) from the market. The petition claims that the injectable medication puts patients at risk of thyroid cancer, pancreatitis, serious allergic reactions, and kidney failure."


The injectable diabetes drug, Byetta (Exenatide), may cause an increased risk of pancreatic cancer in patients using ByettaIf you have lost a loved one from Pancreatic Cancer or have suffered acute pancreatitis, hemorrhagic pancreatitis, accute necrotizing pancreatitis, or pancreas cancer; and have been using Byetta (Exenatide), please report the adverse action to the prescribing medical doctor as soon as possible.

Popular diabetes drugs may raise pancreatic cancer risk – USATODAY.com

When compared to other treatments, the researchers found a sixfold increase of reported cases of pancreatitis (inflammation of the pancreas) linked to patients taking Januvia or Byetta; a 2.9-fold increase in reported cases of pancreatic cancer among those taking Byetta and a 2.7-fold increase of reported pancreatic cancers among Januvia users.
Fatal Diabetes Drug Lawsuits, Fatal Pancreatic Cancer Lawsuits, Diabetes Drug Cancer Lawsuits, and Diabetes Drug Pancreas Cancer Lawsuits

Drug manufacturers that were aware of their diabetes drug causing an increased risk of pancreatic cancer, pancreatitis, and pancreas cancer, but hid research linking this health risk can potentially be held liable by persons that have suffered pancreatitis and pancreatic cancer as well as the families of persons that have died from pancreatic cancer, pancreas cancer, thyroid cancer, or other cancers after using the drug.

The loss of a spouse, child, parent, or loved one to pancreatic cancer, pancreas cancer, or thyroid cancer can be devastating.  It is often worse to then find out that the loss of your loved one was unnecessary and could have been prevented if the defective diabetes drug manufacturer had properly disclosed the drug's potential dangers.  In these situations, where a loved one is lost from taking a defective diabetes drug and the drug company knew of the dangers of the drug, but marketed the diabetes drug as safe to make a profit; families are needed to stand up and make sure that the drug company does not get away with this and will not repeat this action to other families.

In fatal cancer diabetes drug lawsuits, diabetes drug attorneys will often work with families to seek compensation for the loss of their loved one.  Though no amount of money will ever replace or bring back their loved one.  The family will often need compensation to replace the lost earnings of their loved one or to pay medical expenses caused by the care needed by their lost loved one.   The fatal diabetes drug lawsuit will usually seek several elements of damages for the family of the deceased including their loss of love, companionship, comfort, assistance, protection, affection and care; the loss of financial support and lost benefits from the death; and loss of inheritance from an untimely death.  These fatal cancer diabetes drug lawsuits will also often include claims for what the decedent would have recovered had the person survived the cancer caused by the drug. These claims are through the decedent's estate and either go to their heirs or beneficiaries depending if the person had done any estate planning. These damages include expenses associated with the death including funeral costs, medical expenses prior to the death, and pain and suffering associated with the untimely death.  

Saturday, May 5, 2012

Novo Nordisk A/S : VictozaR label in the US updated to include data showing superior efficacy when compared to JanuviaR | Reuters

Novo Nordisk A/S : VictozaR label in the US updated to include data showing superior efficacy when compared to JanuviaR | Reuters


Label update also includes FDA approval of combination therapy with basal insulin for the treatment of adults with type 2 diabetes

Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved to update the product label for VictozaR (liraglutide [rDNA] injection) to include data showing superior blood sugar control and weight reduction when compared to JanuviaR (sitagliptin).

Group asks for withdrawal of Victoza diabetes drug | Reuters

Group asks for withdrawal of Victoza diabetes drug | Reuters


"(Reuters) - Watchdog group Public Citizen urged U.S. regulators to withdraw approval of Novo Nordisk's diabetes drug Victoza, saying it increases the risk of serious health problems like thyroid cancer and kidney failure. Public Citizen said the drug was approved in 2010 against the advice of three reviewers from the U.S. Food and Drug Administration, according a petition filed to the FDA on Thursday."

Monday, April 30, 2012

Janumet, Byetta, and Januvia May Cause Pancreatitis & Pancreas Cancer


Pancreatic cancer is the fourth leading cause of cancer death for both men and women and is one of the most deadly of all types of cancer. This year approximately 45,000 Americans will be diagnosed with pancreatic cancer and about 38,000 will die from it.  Unfortunately, pancreatic cancer is difficult to diagnose, and the diagnosis is often made late in the course of the disease.  Early detection of pancreatic cancer is essential and will greatly improve a person's chances of surviving the disease. 

The diabetes drugs, Januvia, Byetta, and Janumet may cause an increased risk of pancreatic cancer that have taken the diabetes drugs. As such, people that have taken Januvia, Byetta, and Janumet should be aware of the potential danger and be especially aware of the following symptoms: stomach pain, weight loss, dark urine and clay-colored stools, back pain, and jaundice.  Those taking Januvia, Byetta, and Janumet should seek advice from a qualified medical professional as to if they have any signs of pancreatic cancer, if these diabetes drugs are safe for them, and what symptoms they should be aware of to detect any early onset of pancreatic cancer.

The Diabetes Drug Market is Over $40 Billion Each Year and Growing Rapidly Januvia and Janumet had Annual Sales of $4.7 Billion in 2011

More than 300 million people worldwide suffer from diabetes, including about 30 million Americans.  In 2010, the global prevalence of diabetes was estimated to have reached 285 million and predicted to reach 438 million in 2030. The corresponding figures for North America were 37.4 million in 2010 and 53.2 million by 2030 and in Europe 55.2 million in 2010 and 66.2 million in 2030.  The global market for products in the management of diabetes currently stands at $41 billion and is on pace to grow to over $114 billion by 2018. 
 
In 2011, Januvia annual sales rose 39%, to $3.3 billion, from $2.4 billion the year before and $1.9 in 2009. Januvia along with its sister drug Janumet (a combination of Januvia and metformin) has combined for sales of $4.7 billion for 2011.  Sales of Januvia and Merck’s Januvia (sitagliptin) is approved in all major markets and have outdone initial estimates for the drugs.  

Merck’s Januvia (sitagliptin) is approved in all major markets and is the first in a new class of diabetic drugs called dipeptidyl peptidase-4 (DPP-4) inhibitors.  It is approved by the FDA as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

Saturday, April 21, 2012

Pharmas to Feel Lure of Deals in China

Pharmas to feel lure of deals BEIJING - China's drug market is primed for "explosive growth," making companies there attractive targets for drugmakers that will soon lose patents on their most popular treatments, according to KPMG LLP. Products worth more than $30 billion will lose patent cover this year, leading more drugmakers to look into buying or joining with companies in China, the world's third-biggest drug market, according to a KPMG report released on Wednesday.

Tuesday, April 17, 2012

Chinese Authorities are Suspending Sales of 13 Types of Capsules

Probe Launched into Pill Makers' Practices 

"Authorities are suspending sales of 13 types of capsules with reported chromium contamination and are checking the factories accused of producing them.The State Food and Drug Administration issued an urgent notice on Sunday to suspend sales until safety is tested.Police in Xinchang county, Zhejiang province, where China's largest capsule-manufacturing base in Ru'ao township is located, detained 22 people from four capsule factories on Monday, according to Xinhua News Agency.
Meanwhile, the administration and local authorities conducted inspections on 43 capsule factories in the county, closing those exposed by a China Central Television investigation to have made empty capsules using gelatin containing excessive chromium and selling them to pharmaceutical companies."
 

Wednesday, March 28, 2012

The Injectable Diabetes Drug Byetta May Cause Pancreatitis that May Lead to Pancreatic Cancer: Persons Taking Byetta Should Be Aware of Pancreatic Cancer Danger and Consult Their Physician Regarding Potential Pancreas Cancer Risks by Texas Byetta Pancreatic Cancer Lawyer, Byetta Pancreatitis Lawyer and Byetta Pancreas Cancer Lawyer Jason S. Coomer

The Injectable Diabetes Drug Byetta May Cause Pancreatitis that May Lead to Pancreatic Cancer: Persons Taking Byetta Should Be Aware of Pancreatic Cancer Danger and Consult Their Physician Regarding Potential Pancreas Cancer Risks by Texas Byetta Pancreatic Cancer Lawyer, Byetta Pancreatitis Lawyer and Byetta Pancreas Cancer Lawyer Jason S. Coomer

In November 2009, the FDA revised the prescribing information for Byetta to include information on reported cases of acute pancreatitis in patients using this drug.  This revision came after the FDA had received more than 30 reports of acute pancreatitis in Byetta users.  Based on these adverse reports, the FDA directed Amylin to conduct six post-marketing studies regarding acute pancreatitis associated with the use of Byetta, as well as to look at the risk of Byetta cancer, including thyroid cancer and pancreatic cancer. 

Pancreatic Cancer, Exocrine Pancreas Cancers (Pancreatic Adenocarcinoma) and Endocrine Pancreatic Cancers

Pancreatic cancer is the fourth leading cause of cancer death for both men and women and is one of the most deadly of all types of cancer. This year approximately 45,000 Americans will be diagnosed with pancreatic cancer and about 38,000 will probably die from it.

The most common kind of pancreatic cancer is pancreatic adenocarcinoma and includes about 90% of the cases of pancreatic cancer.  Pancreatic adenocarcinoma is a cancerous overgrowth of exocrine pancreatic cells and is unfortunately commonly undetected until it is too late for the patient.  Pancreatic adenocarcinoma because of late detection can often result a fatal diagnosis with very limited survival time. Other forms of exocrine pancreas cancer include: intraductal papillary mucinous neoplasm (IPMN), adenosquamous carcinomas, acinar cell carcinomas, mucinous cystadenocarcinomas, signet ring cell carcinomas, hepatoid carcinomas, colloid carcinomas, undifferentiated carcinomas, pancreatoblastomas, and undifferentiated carcinomas with osteoclast-like giant cells.

Unfortunately, pancreatic cancer is difficult to diagnose, and the diagnosis is often made late in the course of the disease.  Early detection of pancreatic cancer is essential and will greatly improve a person's chances of surviving the disease. As such, people that have taken Byetta, especially those with symptoms of weight loss, dark urine and clay-colored stools, back pain, and jaundice, should seek advice from a qualified medical professional as to if they may have pancreatic cancer and what symptoms they should be aware of to detect any early onset of pancreatic cancer.

Acute Pancreatitis, Hemorrhagic Pancreatitis, Necrotizing Pancreatitis 

Acute pancreatitis is a sudden inflammation of the pancreas that occurs over a short period of time. The pancreas is a digestive organ behind the stomach that secretes essential enzymes needed for the digestion of certain foods, including fats, carbohydrates and proteins. During an episode of acute hemorrhagic pancreatitis, several symptoms relating to digestion and abdomen may occur.  In severe cases, the person may experience confusion, difficulty breathing, or respiratory failure.  The person may also fall into a coma.

The severity of acute pancreatitis may range from mild abdominal discomfort to a severe, life-threatening illness. However, the majority of people with acute pancreatitis (more than 80%) recover completely after receiving the appropriate treatment.  In very severe cases, acute pancreatitis can result in bleeding into the gland, serious tissue damage, infection, and cyst formation. Severe pancreatitis can also create conditions which can harm other vital organs such as the heart, lungs, and kidneys.

The warning signs of pancreatitis include: 1) Upper abdominal pain that radiates into the back. Patients may describe this as a "boring sensation" that may be aggravated by eating, especially foods high in fat. 2) Swollen and tender abdomen 3) Nausea and vomiting 4) Fever  and 5) Increased heart rate.

Acute hemorrhagic pancreatitis is the sudden inflammation of the pancreas. This leads to death of pancreatic tissue and the formation of lesions, causing extensive bleeding. 

Necrotizing pancreatitis is a serious health condition where a person's pancreas is inflamed and bleeding. In Necrotizing Pancreatitis patients, there is inflammation and tissue death, with the pancreas destroying itself.  Whereas in Hemorrhagic Pancreatitis patients, the pancreas is bleeding.  Both are serious conditions and should be treated immediately.

Byetta Pancreatic Cancer Lawsuit Information, Byetta Pancreas Cancer Lawsuit Information, and Byetta Cancer Death Lawsuit Information

Byetta Pancreas Cancer Lawsuits and Byetta Pancreatic Cancer Lawsuits are in the process of being reviewed and filed as recent scientific evidence indicates that the injectable diabetes drug, Byetta (Exenatide), may cause an increased risk of pancreatitis, this side effect can and often does lead to the development of pancreatic cancer.  Pancreatic Cancer is an extremely deadly form of cancer.  Most people diagnosed with Pancreatic Cancer or Cancer of the Pancreas do not survive beyond the five years and many are given much less time as Pancreatic Cancer is hard to detect.  Early detection is the key to surviving pancreatic cancer.

Diabetics are more vulnerable to developing pancreatitis than those without the disease, recent studies indicate that taking Byetta can potentially increase the risk of pancreatitis. And, if pancreatitis becomes chronic, the inflammation of the pancreas will alter its normal structure and functions.  This can lead to pancreatic cancer. 

For more information on this topic, please feel free to go to the following web page: Byetta Pancreatic Cancer Lawsuit, Byetta Pancreas Cancer Lawsuit, and Byetta Cancer Death Lawsuit Information.